ph-762
·Code: PH-762
ph-762: sourced relationships with 1 company · 1 clinical trial tracked.
ph-762 evidence translation
What we can confirm
1 tracked trial
What it means
Source-backed records connect ph-762 to PHIO; that link alone does not prove the drug works.
What to watch
Watch trial status, endpoints, and the next source-backed update.
BioSniper AIPage evidence connected
Prepared research question
How could ph-762 → PHIO affect its developer, and what evidence supports the link?
Run cited research
Traceable citations · Unknowns marked
See linked entities and source evidence1 indications · 0 study sponsors
Related indications
Squamous Cell Carcinoma of the Skin
Study sponsors
No additional listed-company sponsor is linked.
Dated Pipeline Records (1)
| Company | Dated record stage |
|---|---|
| Phio Pharmaceuticals Corp. (PHIO) Squamous Cell Carcinoma of the Skin | Phase 1 |
Clinical Trial Registry Records (1)
Dose Escalation Study of Neoadjuvant Intratumoral PH-762 for Cutaneous Squamous Cell Carcinoma, Melanoma, or Merkel Cell Carcinoma
Primary endpoint: Adverse Events
Interventionalopen22 enrolledStarted 2023-11Completion 2026-035 sites · United StatesPhio Pharmaceuticals Inc.
Frequently asked questions
Which companies have sourced relationships with ph-762?
ph-762 has dated SEC/FDA relationship records for Phio Pharmaceuticals Corp..
How many clinical trials involve ph-762?
BioSniper tracks 1 clinical trial involving ph-762.